ABSTRACT PURPOSE: To evaluate the safety and effi cacy of a novel femtosecond laser-assisted technique for intrastromal administation of ribofl avin and higher fl uence ultraviolet A (UVA) light in collagen cross-linking (CXL) for keratoconus.
METHODS:
Ten eyes with early keratoconus were treated with CXL and followed for a mean of 26 months (range: 18 to 36 months). Using a femtosecond laser, a 100-µm deep, 7-mm diameter intrastromal pocket was created. Two 0.1-mL doses of 0.1% ribofl avin solution were infused into the pocket and the cornea was irradiated with 7 mW/cm 2 UVA light of mean 370 nm wavelength for 15 minutes.
RESULTS:
Mean uncorrected visual acuity improved from 20/40.5 to 20/32.5, best spectacle-corrected visual acuity was unchanged at 20/20, mean sphere was reduced by 0.50 diopters (D), mean cylinder was reduced by 0.90 D, and maximum mean keratometry (K) reduced from 48.70 to 47.90 D. No ectasia progression (defi ned as increase in K over 3-month followup) and no statistically signifi cant change in endothelial cell count was noted during follow-up. The mean thinnest corneal thickness appeared to initially reduce but the mean returned to at least the preoperative level by 18 months. All patients returned to full activities within 1 day postoperative. No adverse effects were noted in any of the cases studied.
CONCLUSIONS: This novel epithelium-sparing, rapid soak-and-treat method of intrastromal ribofl avin instillation and higher fl uence UVA light for CXL appears to be safe and effective. No negative biomechanical effect (ectasia/epithelial ingrowth) was noted due to the femtosecond laser-created pocket. Because minimal epithelial injury occurs using this technique, postoperative pain appears to be signifi cantly reduced. T he management of keratoconus with collagen crosslinking (CXL) utilizing ultraviolet A (UVA) light irradiation and simultaneous topical ribofl avin administration has been studied at length both in the laboratory as well as clinically [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and received CE marking in December 2006 for clinical use in the European Union countries. The standard technique involves partial or complete central epithelial removal followed by topical administration of ribofl avin 0.1% solution to achieve intrastromal penetration. 1 It was theorized that by instilling the ribofl avin solution paracentrally within the cornea, with minimal epithelial surface disturbance, and by using a higher fl uence UVA light source the following could be targeted: 1) faster re-epithelialization and visual rehabilitation for the patient with signifi cant reduction in pain from the procedure; 2) faster diffusion/soak period as the (large molecule, in regard to the Bowman's layer barrier) ribofl avin is directly injected at depth via the intrastromal pocket, providing greater shielding near the endothelium; and 3) selective CXL of the anterior two-thirds of the cornea. We expected minimal toxicity to the endothelium, as no signifi cant concentration of ribofl avin with this technique was expected to be activated by stray UVA light at the deepest stromal level adjacent to the endothelium.
PATIENTS AND METHODS
Ten consecutive "early" keratoconic corneas were selected with the following criteria: topographic evidence of keratoconus (keratometry [K] Ͼ48.00 diopters [D] and/or inferior steepening Ͼ1.00 D) in the superior half of the cornea, minimum corneal thickness у500 µm, and patient age у18 years.
Femtosecond Laser-assisted Intrastromal CXL/Kanellopoulos
SURGICAL TECHNIQUE
Intrastromal Pocket Creation. Under topical 1% proparacaine anesthesia (Alcaine; Alcon Laboratories Inc, Ft Worth, Tex), the IntraLase FS60 (Abbott Medical Optics, Santa Ana, Calif) femtosecond laser was used to create an intrastromal pocket with a nasal hinge at 100-µm corneal depth, 7-mm diameter centered at the pupil, and a 10° temporal side-cut (Fig 1) .
Following the pocket creation, a small Jameson muscle hook (Rumex International Co, St Petersburg, Fla) was used to enter and bluntly dissect the pocket.
Collagen Cross-linking. A 0.1-mL dose of 0.1% ribofl avin solution was administered twice with a 25-gauge air cannula into the intrastromal pocket until it was clearly visualized that the entire pocket was colored bright yellow from the presence and stromal infi ltration of the ribofl avin solution (Fig 2) . After 2 minutes, the UVA light exposure was started. The slit lamp confi rmed rapid homogeneous ribofl avin diffusion within the corneal stroma. Ultraviolet A irradiation source of ~370 nm wavelength (365 to 375 nm) was used to irradiate the corneal surface. The effective fl uence at the corneal surface was calibrated at 7 mW/cm 2 for a duration of 15 minutes. The total amount of UVA irradiation delivered at the corneal plane of a 9-mm diameter was calculated to be 6.3 J.
Postoperative medications included topical ofl oxacin and 1% prednisolone acetate four times a day for 1 week. Patients were evaluated at postoperative day 1, week 1 , months 1 and 3, and every 6 months thereafter to last follow-up.
RESULTS
The Table shows mean pre-and postoperative uncorrected visual acuity (UCVA), mean keratometry, endothelial cell count, and corneal thickness.
Uncorrected visual acuity improved from 20/50 to 20/40, best spectacle-corrected visual acuity was unchanged at 20/20, mean sphere was reduced by 0.50 D, mean cylinder was reduced by 0.90 D, steepest K was reduced from 49.50 to 48.10 D, and no ectasia progression or change in endothelial cell count was noted in any patient during follow-up. An initial reduction of corneal thickness at 1 month at approximately 5% of preoperative measurement was noted. The mean thinnest corneal thickness appeared to increase at 18 months by 5%. All patients returned to full activities within 1 day postoperative. No adverse effects were noted in any of the patients studied. Mean follow-up was 26 months (range: 18 to 36 months).
Slit-lamp microscopy revealed no epithelial defects or diffuse light scattering in the anterior two-thirds of the corneal stroma, which is consistent with our clinical fi ndings using the standard CXL technique.
DISCUSSION
Collagen CXL utilizing UVA irradiation and ribofl avin solution has been applied clinically for the treatment of corneal ectasia, keratoconus, and bullous keratopathy over the past 6 years. [12] [13] [14] [15] [16] We have presented the implementation of this intervention modality as a means to stabilize corneal ectasia associated with LASIK and keratoconus.
14 The documented benefi t in corneal ectatic disorders is nevertheless associated with the shortcomings of epithelial removal and topical ribofl avin administration, lengthy soak/exposure durations under speculum, etc, such as postoperative Figure 1 . Clinical photograph demonstrating the intracorneal "pocket" created with the IntraLase FS60 femtosecond laser (white arrows). Lamellar dissection within the cornea was planned at 100 µm-depth, in a 7-mm diameter centered on the pupil. The side-cut was 10°, which can be seen at the top of the picture (yellow arrow), depicting the actual vertical separation that will make it possible to enter the pocket from the corneal surface. OBL = opaque bubble layer Femtosecond Laser-assisted Intrastromal CXL/Kanellopoulos pain, delayed epithelial healing, and delayed visual rehabilitation for 1 to 2 weeks postoperative.
Is it necessary to remove the epithelium to achieve high intrastromal levels of ribofl avin and facilitate CXL? Ribofl avin is the activating element, but also acts as a "shield" for the underlying ocular tissues such as the endothelium, iris, and crystalline lens. However, it may act as a potential hazard if it couples with UVA light in the level of those structures, as it will generate free radicals. The contributing elements in the collagen CXL photo-oxidative and biochemical reactions are ribofl avin, UVA light, and oxygen and stromal collagen. Does topical administration of ribofl avin on the cornea during the standard CXL procedure coupled with UVA light absorb critical amounts of oxygen? If ribofl avin was already present in the corneal stroma, the UVA light would pass through the corneal endothelium and produce the photochemical reaction in the corneal stroma and not on the eye surface, thereby facilitating more effi cient intrastromal cross-linking.
There have been reports of using ribofl avin solution administered topically through intact epithelium. 3 Is there a way to establish ribofl avin placement intrastromally within a more selective fashion so it will absorb and activate UVA light and achieve CXL without posing a threat to the endothelium and crystalline lens?
In the standard CXL technique, the ribofl avinsoaked corneal stroma absorbs the UVA light and with oxygen produces a photo-oxidative reaction (type 2). The product is a free oxygen radical creation, which then facilitates a biochemical reaction within stromal collagen; it generates fi ber-to-fi ber bonds of stromal collagen and leads to higher stromal rigidity.
Disadvantages of the standard CXL technique include the necessity of epithelial removal as well as the localization of the cross-linking in the anterior corneal surface where most of the UVA light is absorbed by the "denser" concentration of the photosensitizer, ribofl avin. The 3-to 4-day re-epithelialization interval poses the signifi cant risk of infectious keratitis. We reported, along with several investigators, our initial clinical experience utilizing this technique in ectasia after LASIK and primary keratoconus. [4] [5] [6] 10 The novel method described here-selective ribofl avin instillation for CXL and higher fl uence (but of shorter exposure duration) UVA light used-appears to be safe and effective in stabilizing keratoconus.
The femtosecond laser cornea dissection step, performed on the ectatic cornea, may raise concern for further biomechanical destabilization. There is growing evidence that in a femtosecond laser-created fl ap, it is the fi nal side-cut that changes the corneal biomechanics and not the lamellar corneal separation (pocket). In our opinion, the creation of a pocket with just a 10° side-cut at the 7-mm diameter may minimize this concern.
Marshall 17 reported that a femtosecond laser-generated pocket without a side-cut does not alter corneal biomechanics, suggesting there may not be a biomechanical effect from a femtosecond laser-created pocket (very small side-cut). We did not anticipate, or fi nd, a negative biomechanical effect from the femtosecond laser-created pocket as it is associated with a minimal side-cut of 10° at the 7-mm diameter. The CXL was effective in reversal of the ectatic process, although longer followup is necessary to validate this fi nding.
Our novel technique appears to be signifi cantly less painful for patients as it does not require de-epithelialization of the cornea and appears to offer "LASIKlike" rapid rehabilitation. On postoperative day 1, no discomfort was reported and all patients returned to preoperative visual function with no epithelial defect.
We have given consideration to the fact that the traditional technique of "soaking" the de-epithelialized cornea with topical ribofl avin solution provides a formidable concentration of ribofl avin in the stroma so the photochemical reaction between ribofl avin and UVA light takes place. Additionally, it provides high concentrations of ribofl avin in the endothelium and anterior chamber to protect these structures from "stray" UVA light that passes through the overlaying cornea. It is our opinion that UVA light of this fl uence without the presence of ribofl avin is of no harm to the intraocular structures. The presence of adequate concentration of ribofl avin in the 50-to 300-µm corneal thickness range (calculated from the epithelial surface) will absorb most, if not all, UVA light irradiated during the CXL process. Would there be a reduced stromal keratocyte loss to that reported with the standard technique 18, 19 as there is no epithelial removal and a shorter duration of UVA exposure with higher fl uence? Most human cells are believed to be more resistant to short or pulsed exposure to UVA light rather than longer and continuous exposure. 20 In our early clinical experience, this novel technique has been rewarding in regards to patient comfort and evaluated CXL effect. It may diminish epithelial healing complications associated with "standard" CXL such as scars and infectious keratitis.
The potential risks of the femtosecond laser application (suction, corneal dissection, and potential microbial implantation) should be weighed by the clinician. This novel technique may become an alternative for the prevention of corneal transplantation for ectasia. It could possibly be applied as an adjunct prophylactic treatment in routine LASIK cases when corneal ectasia may be a concern. Further studies and longer followup are needed to validate these data.
